From Lifelong Research to Real-World Decisions
In Pittsburgh, where academic rigor and clinical innovation live side by side, Aneurisk™, Inc. is turning a long-standing scientific question into a practical tool for patient care: how do we move beyond size-based rules to understand which aneurysm is likely to change, and when?
For decades, David Vorp, PhD has pushed this question forward, helping shape the field of aneurysm biomechanics and the methods used to study wall stress, tissue strength, and rupture potential. That work, combined with modern imaging and computing, is now finding its home at Aneurisk, where Nathan Liang, MD, a practicing vascular surgeon and the company’s CEO, and Timothy Chung, PhD, co-founder and CTO, are translating these insights into clinician-ready decision support. Working closely with Dr. Vorp, Dr. Chung has applied advanced AI and machine learning methods to streamline the laborious image processing and biomechanical computations that once made this kind of analysis impractical in a clinical setting.
Aneurisk’s approach blends biomechanical modeling with AI-driven prediction, extracting richer signals from standard clinical data and medical imaging. The aim is simple and profoundly important: give clinicians patient-specific insight to inform when to keep watching, when to escalate, and how to plan care, turning complexity into clarity at the point of decision.
LifeX invests behind founders who live the problem and build responsibly toward the clinic. With Aneurisk, that conviction is clear: the company is grounded in deep scientific roots shaped by Dr. David Vorp’s pioneering work in aneurysm biomechanics, strengthened by Dr. Timothy Chung’s technical leadership and innovations in AI-driven modeling, and guided by the clinical insight of Dr. Nathan Liang to ensure the product addresses real challenges faced in vascular practices, and driven by a disciplined focus on translation, developing usable workflows, credible evidence, and the right partnerships to bring advanced modeling into everyday patient care.
Aneurisk reflects what our region does best: connect world-class research to real-world care. It’s a team committed to improving outcomes for patients who deserve more than one-size-fits-all rules and to equipping clinicians with tools that match the complexity of aneurysm disease. LifeX is proud to contribute capital, connections, and commercialization support through the LifeX Continuum. We believe Aneurisk’s work can help clinicians intervene more precisely, reduce uncertainty for patients and families, and ultimately raise the standard of care.
Aneurisk’s solutions are in various stages of research and development and are not yet available for sale. Any references to product capabilities are based on design goals and preclinical data. FDA review and clearance is pending.